Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176677 | 0.86 | CHRM3 (0.39) | CHRM3GRIN1GRIN2BSLC6A4SLC6A2 | |
| SCHEMBL20176377 | 0.78 | SLC6A4 (0.35) | CHRM3SLC6A4 | |
| SCHEMBL20068829 | 0.73 | SLC6A2 (0.36) | CHRM3GRIN1GRIN2BSLC6A4SLC6A2 | |
| SCHEMBL20176333 | 0.73 | SLC6A4 (0.38) | CHRM3GRIN1GRIN2BSLC6A4SLC6A2 | |
| SCHEMBL13855659 | 0.70 | MAPK14 (0.45) | CHRM3SLC6A4SLC6A2SLC6A3EPHX2 | |
| SCHEMBL3037790 | 0.69 | EPHX2 (0.48) | GRIN1GRIN2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL20147404 | 0.69 | SLC6A4 (0.40) | GRIN1GRIN2BSLC6A4 | |
| SCHEMBL20165492 | 0.69 | SLC6A4 (0.42) | CHRM3GRIN1GRIN2BSLC6A4SLC6A2 | |
| SCHEMBL20176885 | 0.69 | SLC6A2 (0.53) | CHRM3GRIN1GRIN2BSLC6A4SLC6A2 | |
| SCHEMBL20168877 | 0.68 | RIPK1 (0.47) | CHRM3GRIN1GRIN2BSLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541784-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2023-09-13 | — | — | EP | disclosed |
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2020-12-29 | — | — | US | disclosed |
| WO-2018091687-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875829-B1 | Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | SLC18A1, CHRM1, CHRM2 | CHRM3 20/4885GRIN1 498/4885GRIN2B 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.